Unlocking value: navigating funding and exit strategies in technology businesses
ReportExplore strategies for scaling in Australia’s tech and SaaS sector in this report, covering capital raising, investor expectations, and long-term growth.
Federal Budget 2026-27: expert insights on spending, tax reform and policy impacts. Visit hub.

In conjunction with Hemmant's List, we are pleased to launch our three-part Commercial disputes and insolvency seminar series. Building on the success of our 2025 series the 2026 series will tackle current, high impact commercial and insolvency issues, pairing leading legal insights with practical financial perspectives.
Seminar one: Construction contract insolvency risks and management leading into the 2032 Brisbane Olympics
As olympic-related infrastructure programs gather pace across Australia, the scale, complexity and time sensitivity of these projects are sharpening commercial and financial risk across the construction sector. Increased funding intensity, compressed delivery timelines and layered contracting arrangements are prompting renewed attention on how stress can emerge and propagate through major projects.
This session will provide a forum to share current market observations and, with regard to the approach taken to construction projects in the 2012 London Olympics, practical perspectives on the intersection of construction risk and financial distress in large scale and event driven infrastructure projects. We will also consider the implications for stakeholders operating within increasingly constrained and dynamic delivery environments.
Explore strategies for scaling in Australia’s tech and SaaS sector in this report, covering capital raising, investor expectations, and long-term growth.
Against a backdrop of rising cost-of-living pressures and economic uncertainty, Not for Profits (NFPs) are facing increasingly complex challenges to maintain financial sustainability. With public expectations rising, funding pathways under strain, and operational costs climbing, many organisations are being forced to reassess how they operate. While the pressures are real, this also creates an opportunity to rethink collaboration, strengthen governance and build long-term resilience.
The biotech industry faces significant challenges, including regulatory pressures, supply chain disruptions, rising costs and shifting investment landscapes.